Eagle pharmaceuticals revenue
WebNov 2, 2024 · -- Q3 2024 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17... WebMar 7, 2024 · Total revenue for the 12 months ended December 31, 2024 was $171.5 million, compared to $187.8 million in 2024. 2024 included a $5.0 million milestone payment from SymBio Pharmaceuticals Limited ...
Eagle pharmaceuticals revenue
Did you know?
WebRevenue in 2024 (TTM): $0.31 B. According to Eagle Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.31 B . In 2024 the company made a …
WebScott Tarriff is the founder of Eagle Pharmaceuticals and has served as its Chief Executive Officer and as a member of the Board since its inception in January 2007. Mr. Tarriff has also served as Eagle’s President since September 2024. Prior to founding Eagle, Mr. Tarriff held several key executive-level positions at publicly traded companies. WebJan 10, 2024 · Eagle exited 2024 with an approximate 6% share of the commercial segment of the pemetrexed market, equating to approximately $8 million per quarter in revenue. Anticipates doubling share by end of Q1 2024. Company values this segment at approximately $550 million annually at expected pricing 8,9.
WebFeb 29, 2016 · Eagle Pharmaceuticals, Inc. Jan 2024 - Present1 year 4 months. United States. +PEMFEXY (Pemetrexed) Launch (February) … WebMar 13, 2024 · Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q4 Non-GAAP EPS of $1.11 beats by $0.28. Revenue of $60.7M (+43.4% Y/Y) misses by $3.56M. Q4 …
WebMay 9, 2024 · Q1 2024 total revenue was $115.9 million, up from $41.2 million in Q1 2024. Achieved sales of $34.3 million of vasopressin, with prior four weeks average market …
WebGranules Pharmaceuticals Inc is the US pharma operations of Granules India. ... • Built sales strategy, delivered four new institutional clients resulting in USD 200K in revenue cynthia larose instagramWebMar 13, 2024 · Fourth Quarter 2024. Total revenue for Q4 2024 was $60.7 million, compared to $42.3 million in Q4 2024. Q4 2024 net income was $8.2 million, or $0.63 per basic and $0.62 per diluted share, compared to net loss of $ (6.2) million, or $ (0.48) per … cynthia larrabeeWebApr 14, 2024 · The company has a market cap of $5.22 billion, a P/E ratio of 12.51 and a beta of 1.31. Eagle Materials ( NYSE:EXP - Get Rating) last posted its quarterly earnings results on Thursday, January 26th. The construction company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.01. cynthia laroseWebMar 2, 2024 · Eagle Pharmaceuticals, which belongs to the Zacks Medical - Products industry, posted revenues of $49.92 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.32%. cynthia larson iowaWebAug 9, 2024 · EAGLE PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share amounts) June 30, 2024: December 31, 2024: ASSETS: Current assets: Cash and cash equivalents $ cynthia larson npiWebMay 10, 2024 · Eagle Pharmaceuticals, which belongs to the Zacks Medical - Products industry, posted revenues of $41.25 million for the quarter ended March 2024, missing … cynthia larose mintzWebMar 13, 2024 · The specialty pharmaceutical company posted revenue of $60.7 million in the period. For the year, the company reported net income of $35.6 million, or $2.73 per share, swinging to a profit in the period. Revenue was reported as $316.6 million. Eagle Pharmaceuticals expects full-year earnings in the range of $4.20 to $4.53 per share. … cynthia larson md